Body mass index and prognosis in HER2-positive metastatic breast cancer patients

被引：0

作者：

Poletto, E. ^{[1
]}

Minisini, A. M. ^{[1
]}

Ferreira, A. ^{[2
]}

Matteo, L. ^{[3
]}

Poggio, F. ^{[3
]}

Sottotetti, F. ^{[4
]}

Montemurro, F. ^{[5
]}

Pozzi, E. ^{[4
]}

Rossi, V. ^{[5
]}

Risi, E. ^{[6
]}

Dellepiane, C. ^{[7
]}

Sini, V. ^{[8
]}

Ziliani, S. ^{[9
]}

Minuti, G. ^{[10
]}

Mura, S. ^{[11
]}

Grasso, D. ^{[12
]}

Bertolini, I. ^{[13
]}

Del Mastro, L. ^{[3
]}

Puglisi, F. ^{[14
]}

机构：

[1] Azienda Osped Santa Maria Della Misericordia, Dept Oncol, Udine, Italy

[2] Hosp Santa Maria, Inst Med Mol, Dept Med Oncol, Lisbon, Portugal

[3] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[4] Fdn Maugeri IRCCS, Unita Dipartimentale Oncol Med, Pavia, Italy

[5] Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo, Italy

[6] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[7] IRCCS AOU San Martino IST, Clin Oncol Med, Genoa, Italy

[8] Univ Roma La Sapienza, St Andrea Hosp, Oncol Unit, I-00185 Rome, Italy

[9] Osped San Paolo, Oncol Med, Savona, Italy

[10] Ist Tumori Toscano, Dept Med Oncol, Livorno, Italy

[11] Osped Santissima Annunziata, Dept Med Oncol, Sassari, Italy

[12] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[13] Azienda Osped Univ Pisana, Dept Oncol, Polo Oncol, Pisa, Italy

[14] Univ Hosp, Dept Oncol, Udine, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30811-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1861

引用

页码：S285 / S286

页数：2

共 50 条

[31] Cardiotoxicity in HER2-positive breast cancer patients
Gonciar, Diana
Mocan, Lucian
Zlibut, Alexandru
Mocan, Teodora
Agoston-Coldea, Lucia
HEART FAILURE REVIEWS, 2021, 26 (04) : 919 - 935
[32] Cardiotoxicity in HER2-positive breast cancer patients
Diana Gonciar
Lucian Mocan
Alexandru Zlibut
Teodora Mocan
Lucia Agoston-Coldea
Heart Failure Reviews, 2021, 26 : 919 - 935
[33] Neratinib in HER2-Positive Breast Cancer Patients
Paranjpe, Rutugandha
Basatneh, Dima
Tao, Gabriel
De Angelis, Carmine
Noormohammed, Sobia
Ekinci, Ekim
Abughosh, Susan
Ghose, Romi
Trivedi, Meghana V.
ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
[34] Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Dhanushkodi, Manikandan
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (05) : 735 - 737
[35] Risk factors for brain relapse in HER2-positive metastatic breast cancer patients
Renata Duchnowska
Rafał Dziadziuszko
Bogumiła Czartoryska-Arłukowicz
Barbara Radecka
Barbara Szostakiewicz
Katarzyna Sosińska-Mielcarek
Agnieszka Karpińska
Elżbieta Starosławska
Tomasz Kubiatowski
Cezary Szczylik
Breast Cancer Research and Treatment, 2009, 117 : 297 - 303
[36] Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
Sawaki, Masataka
BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 37 - 41
[37] Incorporating Neratinib Into Clinical Practice for Patients With HER2-Positive Metastatic Breast Cancer
Isaacs, Claudine
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 15
[38] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
Haq, R.
Gulasingam, P.
CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
[39] Risk factors for brain relapse in HER2-positive metastatic breast cancer patients
Duchnowska, Renata
Dziadziuszko, Rafal
Czartoryska-Arlukowicz, Bogumila
Radecka, Barbara
Szostakiewicz, Barbara
Sosinska-Mielcarek, Katarzyna
Karpinska, Agnieszka
Staroslawska, Elzbieta
Kubiatowski, Tomasz
Szczylik, Cezary
BREAST CANCER RESEARCH AND TREATMENT, 2009, 117 (02) : 297 - 303
[40] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
Carabantes-Ocon, F.
Saez-Lara, E.
Burgos-Garcia, L.
Villar-Chamorro, E.
Casaus-Hazanas, A.
Luna, S.
Martinez, C.
BREAST CANCER RESEARCH, 2007, 9 (01)

← 1 2 3 4 5 →